Exhibition · San Diego, California
Biomarker Assay Development 2011
Health · Medicine · Wellness
Key numbers
- Editions on record
- 2first in 2011
About Biomarker Assay Development
FEATURED PRESENTATION
Safety Biomarkers in Action: Pre-Clinical to Clinical Translation
Calvert Louden, M.D., Senior Director of Pathology, Johnson & Johnson Pharmaceuticals
In toxicology (safety) the paradigm of mechanisms, models and markers is relevant to both safety and efficacy. However, the challenges for safety are significant and there is a strong emphasis to develop and employ new Safety Biomarkers (SBM). These new SBMs could contribute significantly to these challenges and be more informative if they can (1) distinguish between adaptive and toxic response (injury); (2) be predictive as well as diagnostic for injury that is minimal, progressive or reversible; (3) influence the selection of monitorable safety biomarkers for Phase 1 and beyond; (4) provide insights into the possible mode of action/mechanism of toxicity.
From our listing of this edition. Details may have changed since.
Editions
| Year | Dates | Where | Exhibitors | Visitors |
|---|---|---|---|---|
| 2012 | 31 Jan 2012 | Hilton San Diego Resort & Spa San Diego, California | — | — |
| 2011 | 31 Jan – 2 Feb 2011 | Hilton San Diego Resort & Spa San Diego, California | — | — |
Past editions from the bvents archive (2008–2019) and organiser figures where they were published.